ERBB2 and breast carcinoma: Recent data showed that MET in combination with trastuzumab killed cancer stem cells and inactivated ErbB2/IGF-1R interactions in a synergistic manner via inhibiting Src kinase and/or PI3K/Akt pathway, causing overwhelming primary resistance to trastuzumab in HER2 positive breast cancer cells (31, 32).